Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces its Addition to the Russell Microcap® Index

Monday, July 1, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. has announced its inclusion in the Russell Microcap® Index. This recognition highlights the company's advancements in gene editing technology, particularly through its proprietary ARCUS® platform. The firm focuses on developing innovative in vivo gene editing therapies that encompass various sophisticated gene edits.
Price reaction · baseline $9.73 (2024-06-28 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
+1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences has been added to the Russell Microcap® Index.
  • The company utilizes a novel proprietary ARCUS® platform.
  • They are developing advanced in vivo gene editing therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Jul. 1, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

Frequently Asked Questions

What is the Russell Microcap® Index?

The Russell Microcap® Index is a stock market index that measures the performance of the smallest U.S. stocks.

What technology does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS® platform for gene editing.

What therapies is Precision BioSciences developing?

The company is developing in vivo gene editing therapies for gene elimination, insertion, and excision.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform in vivo therapies
Last updated: Jul 1, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →